AXNX News and Press, Axonics Modulation Technologies Inc. From 11/07/19

The following healthcare companies have filed for mixed shelf offerings: More news on: Cytokinetics, Incorporated, Twist Bioscience Corporation, Axonics Modulation Technologies, Inc., Healthcare stocks news, Read more ...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices, today announced that it will release financial results for the third quarter and first nine mont...

Believes Claims are Without Merit and an Attempt to Suppress Innovation and Competition Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing sacral neuromodulation (“SNM”) devices, today announced th...

Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating at Piper Jaffray. More news on: Axonics Modulation Technologies, Inc., Homology Medicines, Inc., Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating and $43 (110% upside) price target at Barclays. More news on: Axonics Modulation Technologies, Inc., GW Pharmaceuticals plc, ShockWave Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more...

Approximately 300 Physicians Registered to Attend Axonics-sponsored Seminars Showcasing Recently FDA-Approved 1 Axonics r-SNM ® System First Commercial Implants in the U.S. Planned for the Week of October 28 Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a med...

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) system, today announced it achieved two milestones that expand its commercial reach in Fran...

Durable Outcomes Highlighted in Plenary Session Presentation; Expanding on Positive Topline Data Released in August More than 350 Physicians Attended a Symposium Highlighting Hands-on Physician Experience with the Recently FDA-Approved Axonics r- SNM ® System 1 Axonics Mod...

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device, today announced that it has entered into an exclusive agreement to supply the Axoni...

One-year Pivotal Study Results from ARTISAN-SNM to be Presented at Plenary Session Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the...